1. 王皓, 单姗, 尤红, 孔媛媛*, 贾继东*, CR-HepB研究组.抗病毒治疗适应证变化对提高慢性乙型肝炎治疗率的影响.临床肝胆病杂志.2022.38(6).1269-1274.核心期刊 |
2. 孟彤彤, 缪宁, 郑徽, 王富珍, 尹遵栋, 沈立萍, 王宇, 贾继东, 孔媛媛*, 张国民*.中国 15~69 岁乙型肝炎表面抗原阳性者对自身感染状态的知晓率及影响因素.中华肝脏病杂志.2022.30(5).534-540.核心期刊 |
3. Yuanyuan Kong, Tingting Lv, Min Li, Lianghui Zhao, Tongtong Meng, Shanshan Wu, Wei Wei , Qian Zhang, Sha Chen, Hong You, Sabela Lens, Hitoshi Yoshiji, Sven Francque, Emmanouil Tsochatzis, Shiv K Sarin*, Mattias Mandorfer*, Jidong Jia*; BAVENO Cooperation: an EASL consortium.Systematic review and meta-analysis: impact of anti-viral therapy on portal hypertensive complications in HBV patients with advanced chronic liver disease.Hepatol Int. .2022.16(5).1052-1063.SCI |
4. Xinyu Zhao#, Min Li#, Hao Wang, Xiaoqian Xu, Xiaoning Wu, Yameng Sun, Canjian Ning, Bingqiong Wang, Shuyan Chen, Hong You, Jidong Jia*, Yuanyuan Kong*.Impact of National Centralized Drug Procurement Policy on Antiviral Utilization and Expenditure for Hepatitis B in China.Journal of Clinical and Translational Hepatology .2022.10(3).420-428.SCI |
5. Min Li, Lianhui Zhao, Jialing Zhou, Yameng Sun, Xiaoning Wu, Xiaojuan Ou, Hong You, Yuanyuan Kong*, Jidong Jia*.Changing clinical care cascade of patients with chronic hepatitis B in Beijing, China.Lancet Reg Health West Pac..2021.16.100249.SCI |
6. 李敏, 苏健婷, 武珊珊, 韦在华, 孔媛媛*, 贾继东*.乙型肝炎肝硬化患者年龄和性别与肝病相关死亡风险的关系.中华肝脏病杂志.2021.29(5).403-408.核心期刊 |
7. 陈莎, 赵连晖, 单姗, 李敏, 孙亚朦, 周家玲, 吴晓宁, 董瑞华, 孔媛媛*, 欧晓娟, 马红, 尤红, 贾继东*.治愈慢性乙型肝炎新药临床试验方案的系统评价.中华肝脏病杂志.2020.28(8).662-666.核心期刊 |
8. 孔媛媛, 魏巍, 单姗, 马红, 欧晓娟, 徐小元, 段钟平, 侯金林, 魏来, 尤红, 贾继东*.乙型肝炎肝硬化患者的临床特征与抗病毒治疗模式变化.肝脏.2020.25(2).123-127.核心期刊 |
9. 武珊珊, 孔媛媛*.构建慢性乙型肝炎临床终点事件预测模型的方法学考量.临床肝胆病杂志.2020.36(9).1923-1927.核心期刊 |
10. 孔媛媛, 孙亚朦, 周家玲, 吴晓宁, 马红, 欧晓娟, 贾继东*, 尤红*.慢性乙型肝炎患者肝脏硬度值下降趋势与肝纤维化逆转结局的关系.临床肝胆病杂志.2020.36(2).314-318.核心期刊 |
11. Min Li, Tingting Lv, Shanshan Wu, Wei Wei, Xiaohai Wu, Xiaojuan Ou, Hong Ma, Shein-Chung Chow, Yuanyuan Kong*, Hong You*, Jidong Jia*.Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis.Hepatol International.2020.14(1).105-114.SCI |
12. Lv T, Li M, Zeng N, Zhang J, Li S, Chen S, Zhang C, Shan S, Duan W, Wang Q, Wu S, You H, Ou X, Ma H, Zhang D, Kong Y*, Jia J*.Systematic review and meta-analysis on the incidence and prevalence of autoimmune hepatitis in Asian, European, and American population.JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY.2019.34(10).1676-1684.SCI |
13. Kong Y, Jia J, Yang HI*.Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B.JAMA Oncology.2019.5(6).915-916.SCI |
14. Zhang Q, Liu Z, Wu S, Duan W, Chen S, Ou X, You H, Kong Y*, Jia J*.Meta-Analysis of Antinuclear Antibodies in the Diagnosis of Antimitochondrial Antibody-Negative Primary Biliary Cholangitis.Gastroenterol Res Pract..2019.eCollection.8959103.SCI |
15. Yuanyuan Kong, Yameng Sun, Jialing Zhou, Xiaoning Wu, Yongpeng Chen, Hongxin Piao, Lungen Lu, Huiguo Ding, Yuemin Nan, Wei Jiang, Youqing Xu, Wen Xie, Hanwei Li, Bo Feng, Guangfeng Shi, Guofeng Chen, Hai Li, Huanwei Zheng, Jilin Cheng, Tailing Wang, Hui Liu, Fudong Lv, Chen Shao, Yimin Mao, et al.Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir.Journal of Viral Hepatitis.2019.26(5).576-585.SCI |
16. Li M#, Kong YY#, Wu SS, Zhou JL, Wu XN, Wang L, Su JT, Ou XJ, You H, Xie XQ, Wei ZH*, Jia JD*.Impact of reimbursement program on liver-related mortality in patients with chronic hepatitis B in Beijing, China.Journal of Digestive Diseases.2019.20(9).467-475.SCI |
17. Wei W, Wu X, Zhou J, Sun Y, Kong Y*, Yang X*.Noninvasive Evaluation of Liver Fibrosis Reverse Using Artificial Neural Network Model for Chronic Hepatitis B Patients.Comput Math Methods Med..2019.eCollection .7239780.SCI |